Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference

CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that company management will be presenting a corporate overview and participating in one-on-one meetings at the Biocom California Global Life Science Partnering Conference in San Diego, California February 22 – 24, 2022. Meetings with management will be taking place in-person and virtually.

Biocom Global Healthcare Conference (in-person)

For information about the Biocom Global Partnering Conference, and to register to meet with Dyve Biosciences management in-person or virtually, please refer to the conference website.

About Dyve Biosciences 

Dyve is a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, including a collection of new chemical entities (NCEs) in collaboration with a major pharmaceutical company. Dyve has an emulsion-based platform technology that has succeeded where previous attempts with patches and microneedles have failed – allowing for the topical application and transdermal delivery of both simple and complex molecules that are neither suitable nor optimal for traditional oral and injectable routes of administration. Dyve’s transdermal delivery system provides a new paradigm for a universal third route of drug delivery, combining the fast onset of action and systemic availability of an injectable, with the convenience and optimal pharmacokinetic profile of an oral pill. Dyve’s goal is to set a new standard with a comprehensive transdermal delivery solution, creating therapeutics which are both patient-friendly and clinically intuitive for a wide array of indications. Dyve’s technology includes a novel approach for delivering pH-adjusting agents through the skin. This has the potential to decrease the acidic microenvironments that are key to the pathology and treatment of multiple disease states within oncology, immunology, and inflammation. For example, Dyve’s lead asset, pH-modulator DYV702, recently completed a successful multi-center, 100-patient, Phase 2 clinical study for reducing the pain associated with acute gouty arthritis. Dyve’s novel technology platform carries a robust portfolio of both pending and issued patents. For more information, please visit www.dyvebio.com. 

Corporate Contact
Jim McGee
Dyve Biosciences, Inc.
805-857-6449
jim.mcgee@dyvebio.com

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com